PROGRAM OVERVIEW

The NLA is excited to share that we will host our first-ever virtual Scientific Sessions! Due to current travel restrictions and gathering limitations in the city of Chicago, the NLA has made the difficult decision to rescope our 2020 Scientific Sessions into a fully virtual conference held live on Thursday, December 10 – Saturday, December 12, 2020.

There will be a reduced meeting registration for the virtual conference at a discounted rate of only $299.  Registration for the virtual sessions will open at the end of August.

If you are currently registered for the live 2020 NLA Scientific Sessions:
Please reach out to meetings@lipid.org to let us know if you would like to transfer your registration to the virtual conference (and receive a refund for the difference in cost) or receive a full refund if you are unable to attend.  If we haven’t heard from you by Friday, September 5, 2020 we will automatically transfer your registration to the virtual conference and refund you the difference in the registration fee.  

If you booked a hotel room at the host hotel, the Chicago Marriott Magnificent Mile:
All hotel reservations made at our host hotel, Chicago Marriott Magnificent Mile, will be automatically cancelled on Monday, August 24th and refunded via your original method of payment within 30 days.   

Please continue to monitor this page for updates.

You may need to disable administrative overlay in your Drupal record

Edit Parent - PROGRAM (visibility Show)

Agenda


*PLEASE NOTE* The course will be held using the CENTRAL time zone.
Thursday, December 10, 2020
9:35AM - 9:45AM Opening Remarks
9:45AM - 11:10AM Session I- Cardiovascular Preventive Care in Pregnancy
9:45AM - 9:50AM Pre-Session Assessment  

9:50AM - 10:10AM

Pregnancy and Contraception - How Should we Counsel Women with Severe Dyslipidemia? Jennifer L.  Thompson, MD
10:10AM - 10:30AM Medical Therapy during Pregnancy Pamela B. Morris, MD, FNLA*
10:30AM - 10:50AM Medical Nutrition Therapy During High Risk Pregnancy with Severe Hypertriglyceridemia Wahida Karmally, PhD, MS, RDN, CDE, CLS
10:50AM - 11:10AM Post Session Assessment and Question & Answer Panel
11:10AM - 11:15AM Break
11:15AM - 1:00PM Session II- Ethical Dilemmas in Lipidology
11:15AM - 11:20AM Pre-Session Assessment
11:20AM - 11:40AM CVD Risk Reduction – Is Ovum Selection Ethical for FH? James A. Trippi, MD, FNLA*
11:40AM - 12:00PM Can we Justify FH Genetic Testing Prior to the Age of Consent? G. Kevin Donovan, MD, MA
12:00PM - 12:20PM Statins and Reproductive Health in Teens - An Accident Waiting to Happen? Ann Liebeskind, MD, FNLA*
12:20PM - 12:40PM Does Cholesterol Screening Potentially Limit Job Opportunities? Don P. Wilson, MD, FNLA*
12:40PM - 1:00PM Post Session Assessment and Question & Answer Panel
1:00PM - 2:00PM Expert Theaters
2:00PM - 3:30PM

CME/CE Symposium- Bridging the Gaps in Management of Familial Chylomicronemia Syndrome: A Team-Based Patient-Focused Approach hosted by the National Lipid Association
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2020 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.

4:00PM - 6:00PM NLA Opening Session – Impact of Genetics on Clinical Practice- Chair Dr. Christie Ballantyne
4:00PM - 4:05PM Pre-Session Assessment  
4:05PM - 4:15PM Case Presentation Aliza Hussain, MD
4:15PM - 4:35PM Genetic Testing for Lipid Disorders Zahid Ahmad, MD
4:35PM - 4:55PM Polygenic Risk Scores for CVD, Use in Practice and Potential Impact on Healthcare Joshua W. Knowles, MD
4:55PM - 5:15PM My Patients are Ordering Direct-to-Consumer Genetic Testing- What Now? Emily E. Brown, MGC, CGC
5:15PM - 5:35PM Genetics and Biotech therapies Christie M. Ballantyne, MD, FNLA*
5:35PM - 5:40PM Post Session Assessment
5:40PM - 6:00PM Question & Answer Panel
6:00PM - 7:00PM NLA Virtual Honors and Awards Ceremony
7:00PM - 8:30PM CME/CE Symposium- Dialogues from the Dais: CVD Risk Reduction in the Hypertriglyceridemic Patient hosted by Medtelligence
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2020 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
Friday, December 11, 2020
7:00AM - 9:00AM CME/CE Symposium- The Ever-Evolving Treatment Landscape of Lipid-Lowering Therapies hosted by Medscape
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2020 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
8:00AM - 8:50AM Abstract Author Q&A in Virtual Poster Hall / Exhibit Hall
8:50AM - 9:00AM Opening Remarks
9:00AM - 10:25AM Session III- Non-Alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease: What Clinicians Need to Know
9:00AM - 9:05AM Pre-Session Assessment
9:05AM - 9:15AM Case Presentation of Patient with Non-Alcoholic Fatty Liver Disease Pam R. Taub, MD
9:15AM - 9:35AM Diagnosing NAFLD and NASH in Clinical Practice and When to Refer to a Specialist John M. Vierling, MD
9:35AM - 9:50AM Evidence Based Drug Therapy Treatment Options for NAFLD Michael Wilkinson, MD
9:50AM - 10:10AM Lifestyle Interventions for NAFLD: Evaluation of the Evidence Lisa B. VanWagner, MD, MSc
10:10AM - 10:25AM Post Session Assessment and Question & Answer Panel
10:25AM - 10:30AM Break
10:30AM - 10:55AM NLA Presidents Address
10:55AM - 11:30AM W. Virgil Brown Distinguished Award and Lectureship John R. Guyton, MD, FNLA
11:30AM - 12:05PM Exhibit Hall
12:05PM - 1:30PM Session IV- Imaging Atherosclerosis: What We Know and Gaps in Knowledge
12:05PM - 12:10PM Pre-Session Assessment
12:10PM - 12:30PM

Tracking Atherosclerosis with Cardiac CT

Matthew J. Budoff, MD
12:30PM - 12:50PM Carotid Ultrasound and Brachial FMD James H. Stein, MD
12:50PM - 1:10PM Imaging in Pediatrics- Where we Are and Where we Need to go Elaine M. Urbina, MD, MS
1:10PM - 1:30PM Post Session Assessment and Question & Answer Panel
1:30PM - 2:40PM Exhibit Hall
1:30PM - 2:30PM Expert Theaters
2:40PM - 4:05PM Session V- Let’s Talk About Sex…Hormones
2:40PM - 2:45PM Pre-Session Assessment
2:45PM - 3:05PM Hormone Replacement in Postmenopausal Women: Panacea or Poison? Eliot A. Brinton, MD, FNLA
3:05PM - 3:25PM Testosterone Treatment in Men Maamoun Salam, MD
3:25PM - 3:45PM Effects of Hormonal Therapy for Transgender Transition Eugenia Gianos, MD, FNLA
3:45PM - 4:05PM Post Session Assessment and Question & Answer Panel
4:05PM - 4:15PM Break
4:15PM - 5:40PM Session VI- Prevention of Atherosclerotic Cardiovascular Disease in South Asians in the US
4:15PM - 4:20PM Pre-Session Assessment
4:20PM - 4:40PM Epidemic of ASCVD in South Asians in the US and Strategies for Early Identification Dinesh Kalra, MD
4:40PM - 5:00PM Diabetes and Heart Disease in South Asians in the US:  Challenges and Opportunities in Management Krishnaswami Vijayaraghavan, MD, MS, FNLA
5:00PM - 5:20PM Dyslipidemia in South Asians in the US Nihar R. Desai, MD, MPH
5:20PM - 5:40PM Post Session Assessment and Question & Answer Panel
6:00PM - 7:20PM CME/CE Symposium- Genetic Dyslipidemias- Familial Hypercholesterolemia and Beyond hosted by the National Lipid Association
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2020 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
7:30PM - 8:30PM New Member & Women in Lipidology Event
Saturday, December 12, 2020
7:00AM - 8:00AM Exhibit Hall
8:00AM - 8:10AM Stretch Video
8:10AM - 10:10AM CME/CE Symposium- Mastering the Management of Hyperlipidemia in Statin-Treated or Statin-Intolerant Patients: Recent Treatment Advances for Patients That Remain at High-Risk of ASCVD hosted by the National Lipid Association
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2020 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
10:10AM - 10:20AM Opening Remarks
10:20AM - 11:10AM Abstract Author Q&A in Virtual Poster Hall
11:10AM - 12:20PM Session VIII- Abstract Award Presentations
12:20PM - 1:30PM Exhibit Hall
12:20PM - 1:20PM Expert Theaters
1:30PM - 3:00PM Special Non-CME Joint Session between EAS and NLA- Dyslipidemia Treatment in Light of the New Guidelines- Chairs: Lale Tokgözoğlu, MD and Antonio M. Gotto, Jr., MD, DPhil, FNLA
1:30PM - 1:35PM Session Introduction from Chairs  
Targets and Goals
1:35PM - 1:50PM EAS Perspectives Alberico L. Catapano, PhD
1:50PM - 2:05PM NLA Perspectives Carl E. Orringer, MD, FNLA
Therapeutic Approaches
2:05PM - 2:50PM EAS Recommendations & Perspectives Lale Tokgözoğlu, MD
2:50PM - 2:35PM NLA Recommendations & Perspectives Peter H. Jones, MD, FNLA
2:35PM - 3:00PM Question & Answer Panel
3:00PM - 3:05PM Break
3:05PM - 4:05PM Session IX- Scientific Statements
3:05PM - 3:10PM Introduction of the NLA Scientific Statement on CAC Carl E. Orringer, MD, FNLA
3:10PM - 3:30PM NLA Scientific Statement on CAC: CAC Testing and Interpretation Matthew J. Budoff, MD
3:30PM - 3:50PM NLA Scientific Statement on CAC: CAC Guided Treatment Recommendations and other Considerations Michael Blaha, MD
3:50PM - 4:05PM Question & Answer Panel
4:05PM - 4:25PM Junior Faculty Research Award Presentation Nathan Stitziel, MD, PhD
4:25PM - 4:30PM Break
4:30PM - 5:00PM Late Breakers

 

Ancillary Courses


Foundations of Lipidology Course

Pre-conference Course

Thursday, November 19 • 8:00 am–5:35 pm

Friday, November 20 • 8:00 am–2:30 pm

$550 NLA Members, $950 Non-Members, $0 Trainees

 

Overview

The NLA's Foundations of Lipidology course provides an introductory review of the core curriculum in Clinical Lipidology. This course is designed for any healthcare professional seeking to learn the fundamentals of Lipidology. Experts in Lipidology will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in a lipid practice and prepare for advanced training.

This course is particularly useful to review core elements of Clinical Lipidology and is appropriate for clinicians from the full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Pharmacist, Exercise Physiologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into Lipidology.

The Foundations of Lipidology is offered as a two-day course prior to NLA meetings (Clinical Lipid Updates [CLU] and Scientific Sessions).

Masters in Lipidology Course

Pre-conference Course

Thursday, December 3 • 7:30 am–5:40 pm

Friday, December 4 • 7:30 am–2:20 pm

$750 NLA Members, $1,250 Non-Members, $395 Trainees

 

Overview

The NLA's Masters in Lipidology course provides an advanced examination of the core curriculum in Clinical Lipidology. This course is designed for any health care professional with experience in Lipidology who desires advanced training. Experts in the field of Lipidology will lecture on advanced concepts and guide participants through interactive learning scenarios that provide tools and skills to further advance personal standards of practice. It is recommended that attendees have already completed preparatory coursework (e.g., Foundations of Lipidology or similar core curriculum training).

This course is particularly useful to explore the details of Clinical Lipidology and is appropriate for clinicians from the full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Exercise Physiologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into Lipidology.

Masters in Lipidology is offered as a two-day course prior to NLA meetings (Clinical Lipid Updates [CLU] and Scientific Sessions).

For additional information, click the course logo below.

For additional information, click the course logo below.

Accreditation Information


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this Other activity (Annual Meeting Simulive Virtual Conference) for a maximum of 15.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 15.00 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement

Universal Activity Number JA0007192-0000-20-005-H01-P (Application)
This Activity has been approved for 15.25 contact hour(s) (1.525 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 15.2 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

 

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity, Application

Educational Objectives

At the conclusion of this activity, all participants should be able to:

  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

Session I: Cardiovascular Preventive Care in Pregnancy

  • Discuss potential cardiovascular risks associated with pregnancy in women with genetic dyslipidemia.
  • Review strategies for managing CVD risk in pregnant women or women who plan to become pregnant.

Session II: Ethical Dilemmas in Lipidology

  • Discuss ethical controversies in the practice of lipidology.

NLA Opening Session: Impact of Genetics on Clinical Practice

  • Evaluate the use of genetic testing to inform risk assessment and therapeutic decisions.
  • Explain the role of the genetic counselor in screening for genetic disorders.
  • Review challenges in the application of genomic testing into clinical practice.
  • Apply insight from human genetics to identify novel therapeutic targets.

Session III: Non-Alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease: What Clinicians Need to Know

  • Identify appropriate lipid management for patients with non-alcoholic fatty liver disease.
  • Review appropriate diagnostic strategies in patients with non-alcoholic fatty liver disease.
  • Determine therapeutic options for the treatment of non-alcoholic fatty liver disease.

W. Virgil Brown Distinguished Achievement Award and Lectureship

  • Evaluate the management of patients with dyslipidemia.

Session IV: Imaging Atherosclerosis: What We Know and Gaps in Knowledge

  • Review the use of imaging modalities for cardiovascular risk assessment.

Session V: Let’s Talk About Sex…Hormones

  • Discuss the efficacy and safety of hormonal therapies in the management of dyslipidemia and cardiovascular risk.

Session VI: Prevention of Atherosclerotic Cardiovascular Disease in South Asians in the US

  • Recognize the risk factors and interconnection of early onset diabetes and ASCVD in South Asians.
  • Discuss epidemiology and risk profiles for dyslipidemia in South Asians in the United States.

Session VII: Ask the Magic Lipid Ball: An Interactive Audience Session

  • Appraise current and emerging pharmacologic management options for dyslipidemia.

Session VIII: Oral Poster Presentations

  • Critically appraise emerging research and its applications to daily clinical practice.

Special Joint Session Between EAS and NLA: Dyslipidemia Treatment in Light of the New Guidelines

  • Describe current guidelines for the management of dyslipidemia.

Session IX: Scientific Statements of the NLA

  • Review current literature of importance to the science and practice of clinical lipidology.

NLA Junior Faculty Research Award Presentation

  • Discuss the recent research impacting future management of patients with dyslipidemia.
Delete PROGRAM

Edit Parent - SPECIAL EVENTS (visibility Show)

Symposia


    The following events are independent satellite CME/CE symposia held in conjunction with the NLA 2020 Scientific Sessions. They are not part of the official sessions as planned by the NLA Scientific Meetings Committee. 

 

Bridging the Gaps in Management of Familial Chylomicronemia Syndrome: A Team-Based Patient-Focused Approach

Thursday, December 10, 2020

2:00 – 3:30pm CST

 

Genetic dyslipidemias are often under-recognized and misdiagnosed in clinical practice leading to heightened burden of disease for patients and ineffective treatment strategies. Join our panel featuring a Familial Chylomicronemia Syndrome (FCS) patient advocate for a 1.5-hour CME symposium covering:

  • FCS case studies with a patient presentation
  • Making an Early Diagnosis with clinical & genetic confirmations
  • The importance of systematic communications between hospitalists, gastroenterologists, and lipid specialists
  • Clinical guidance on patient-led management and the future of pharmacotherapy for patients with FCS

Have questions for our panel? Stay for a robust panel discussion and Q&A segment with the audience. You will leave this session better able to demonstrate knowledge of the mechanisms and manifestations of FCS and counsel patients with FCS on comprehensive management plans.

 
Faculty
Daniel Gaudet, MD, PhD
Anne C. Goldberg, MD, FNLA (Chair)
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA
Darlene Voll 
Lauren Williams, MCN, RDN, LD
 

This activity is supported by educational funding provided by Akcea Therapeutics. 

 

Dialogues from the Dais: CVD Risk Reduction in the Hypertriglyceridemic Patient

Thursday, December 10, 2020

7:00 – 8:30pm CST

 

This highly interactive CME-certified symposium will feature renown lipid experts who will address and discuss hot topics in lipid management. Topics include the remarkable clinical and biologic findings of omega-3 fatty acids to reduce ASCVD events, making sense of recent guidelines, more evidence on the role of triglyceride-rich lipoproteins in ASCVD, and new horizons for lipid management. This activity will provide the opportunity for the multidisciplinary faculty and symposium participants to work through complex issues and cases that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol, many (or most) of whom have been sub-optimally managed.

Faculty

Sergio Fazio, MD, PhD - Chair
Eliot A. Brinton, MD, FAHA, FNLA, FACE
Michael Miller, MD, FACC, FAHA
Margo B. Minissian, PhD, ACNP, FNLA, FAHA
John R. Nelson, MD

Co-Hosted by Medtelligence

This activity is supported by educational funding provided by Amarin Pharma Inc. 

 
 

The Ever-Evolving Treatment Landscape of Lipid-Lowering Therapies

Friday, December 11, 2020

7:30 – 8:50am CST

 

Don't know what you don't know about treating dyslipidemia? Join our virtual symposium to hear a panel of faculty experts discuss:

  • Current gaps in dyslipidemia care 
  • What "perfect" lipid-lowering therapy looks like
  • Guideline recommendations for LDL-C goal setting
  • Mechanisms of action of novel lipid-lowering therapies
  • Patient case studies: when nonstatin therapy is needed to reach individualized goals

This dynamic, interactive symposium will use engaging TED Talk-style segments, traditional didactic reviews, and interactive case studies to provide learners with the latest and greatest on lipid lowering therapies, focusing on clinical differences that matter to you as well as best practices in clinical utilization as part of individualized, comprehensive lipid-lowering treatment plans. 

 

Faculty

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA 
Kim K. Birtcher, M.S, Pharm.D, AACC, FNLA, BCPS-AQ Cardiology, CDCES 
Rachel M. Bond MD, FACC    

Co-Hosted by Medscape

This activity is supported by educational funding provided by Esperion. 

 

Genetic Dyslipidemias:  Familial Hypercholesterolemia & Beyond

Friday, December 11, 2020

6:00 – 7:20pm CST

 

Join the NLA to solve the mystery of genetic dyslipidemias. Our panel will explore the mechanisms and manifestations of Familial Hypercholesterolemia (Heterozygous and Homozygous), Sitosterolemia, Lysosomal Acid Lipase Deficiency, and Cerebrotendinous xanthomatosis (CTX). After reviewing patient profiles, you will make your diagnosis and receive real-time critiques from our panel. Before the evening is over, we will explore expert recommendations for clinical and genetic diagnosis confirmations, management strategies, and methods to maximize patient engagement throughout the life cycle.

 

Faculty
Karen E. Aspry, MD, MS, FACC, FNLA

P. Barton Duell, MD, FNLA

Don P. Wilson, MD, FNLA (Program Chair)

 

This activity is supported by educational funding provided by Alexion Pharmaceuticals and Amryt Pharma DAC. 

 

Mastering the Management of Hyperlipidemia in Statin-Treated or Statin-Intolerant Patients: Recent Treatment Advances for Patients That Remain at High-Risk of ASCVD

Saturday, December 12, 2020

7:00 – 9:00am CST

Patients with ASCVD are at high risk for CV events. Lowering LDL-C can reduce this risk and, in some, reduce all-cause mortality. Despite current lipid-lowering guidelines and recommendations, many high-risk patients fail to achieve their targeted LDL-C levels with stain therapies. Our multidisciplinary panel will review the role of newer non-statin therapies including PCSK9 targeting agents, discuss current perspectives and guidelines, and provide practical insights on managing hyperlipidemia in high-risk ASCVD patients using novel agents.

Learn more and RSVP here: peerview.com/Hyperlipidemia2020

Faculty

Chair

Professor Kausik Ray

European Atherosclerosis Society
Imperial Centre for Cardiovascular Disease Prevention
Imperial College London
London, England, United Kingdom

 

Alan S. Brown, MD, FACC, FAHA, FNLA, FASPC

Advocate Heart Institute at Advocate Lutheran General Hospital
Advocate Medical Group
Loyola Stritch School of Medicine
Park Ridge, Illinois

 

Christie M. Ballantyne, MD, FACP, FACC

Baylor College of Medicine
Houston, Texas

 

Co-Hosted by PeerView

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Expert Theaters


  The following events are independent Expert Theater presentations held in conjunction with the NLA 2020 Scientific Sessions. They are not part of the official sessions as planned by the NLA Scientific Meetings Committee and are not offered for CME/CE credit. 

Thursday, December 10 • 1:00 - 2:00 pm CT

 

Optimizing LDL-C Management in Recent MI Patients: A Focus on Multidisciplinary Care Team Approach 

Speaker: Dr. James A. Underberg, MS, MD, FACPM, FASPC, FASH, FNLA 

 This session will cover:

  • Managing LDL-C According to Updated Multi-Society Cholesterol Guidelines
  • Understanding the Risk of Another CV Event in Patients With Recent MI/ACS
  • Real-World Data in LDL-C Management
  • Clinical Data on CV Outcomes and LDL-C Management in Patients with Recent MI/ACS
  • Ensuring Continuity of Care through a Multidisciplinary Care Team Approach 

 

Hosted by Amgen

_______________________________________________________________________________________________________

Friday, December 11 • 1:30 - 2:30 pm CT

 

An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C

Speaker: Alan S. Brown, MD, FACC, FAHA, FNLA, FASPC

 The session will cover the following information:

• Cardiovascular disease and its mortality and morbidity

• Unique mechanism of action for two treatment options

• Efficacy data for two treatment options

• Safety data for two treatment options

• Overview of the ongoing Outcomes trial

 

Hosted by Esperion Therapeutics

 

 

Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and the Importance of Reducing the Burden of Elevated LDL-C Levels

This program highlights the burden of cardiovascular disease in patients with diabetes who have an elevated risk of ASCVD and cardiovascular events. The mechanistic role of elevated LDL-C in ASCVD progression and the importance of lowering LDL-C levels is emphasized, and the use of LDL-C–lowering therapies to reduce risk in patients with diabetes is described, in context with currently published guidelines.

Speaker: 

Guy L. Mintz, MD, FACP, FACC, FNLA, FASPC
Clinical Associate Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Director, Cardiovascular Health and Lipidology of Cardiology
North Shore University Hospital,
Manhasset, NY

 

Hosted by Novartis Pharmaceuticals Corporation 

 

______________________________________________________

Saturday, December 12 • 12:20 - 1:20 pm CT

 

VASCEPA (icosapent ethyl): Elevating the Standard of Care

Speaker: Dean Karalis, MD, FACC, FNLA

 

Hosted by Amarin Pharma Inc. 

 

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease 

The program includes a description of the Lp(a) particle, its association with CV risk, and how measuring Lp(a) can help predict someone’s CVD risk profile.

Speaker: 

Keith C. Ferdinand MD, FACC, FAHA
Gerald S. Berenson Chair in Preventive Cardiology
Tulane University School of Medicine
New Orleans, LA

 

Hosted by Novartis Pharmaceuticals Corporation 

 

Late Breakers


Saturday, December 12

4:30 - 5:15pm

Moderator: Marlys L. Koschinsky, PhD

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent EthylIntervention Trial 

Speaker: Michael Miller, MD, FACC, FAHA

Reductions in lipoprotein(a) with inclisiran– Analysis from ORION-10 and ORION-11

Speaker: Professor F. J. Raal

 

First Human Trial of a Loading Dose of Icosapent Ethyl in Patients with COVID-19: Primary Results of the VASCEPA COVID-19 CardioLink-9 Randomized Trial

Speaker: Deepak L. Bhatt, MD, MPH 

Delete SPECIAL EVENTS


SCIENTIFIC MEETINGS CO-CHAIRS

Christie M. Ballantyne, MD, FNLA

Committee Co-Chair
Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Houston, TX

Anne C. Goldberg, MD, FACP, FNLA

Committee Co-Chair
President, Foundation of the NLA

Professor of Medicine
Washington University School of Medicine
St. Louis, MO



PROGRAM PLANNERS

Casey Elkins, DNP, MEd, NP-C, CLS, FNLA

Program Planner
Assistant Dean for Academic Affairs
Director, DNP Program
University of South Alabama
College of Nursing
Mobile, AL

Peter H. Jones, MD, FNLA

Program Planner
Associate Professor
Baylor College of Medicine
Houston, TX

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

Program Planner
Director/Clinical Associate Professor
Wellness Center
Idaho State University
Kasiska Division of Health Sciences
Pocatello, ID

Ann M. Liebeskind, MD, FNLA

President, Midwest Chapter Lipid Association
Founder
Mobile Health Team Lipids Clinic
Neenah, WI
Clinical Adjunct Assistant Professor
University of Wisconsin
School of Medicine and Public Health
Madison, WI

Pamela B. Morris, MD, FNLA

Program Planner
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Mt. Pleasant, SC

Alan T. Remaley, MD, PhD

Program Planner
Section Chief Lipoprotein Metabolism Laboratory
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD

Joseph J. Saseen, PharmD, CLS, FNLA

Program Planner
President, National Lipid Association

Professor and Vice Chair
Clinical & Academic Programs
Department of Clinical Pharmacy
University of Colorado Anschutz Medical Campus
Skaggs School of Pharmacy
Aurora, CO

Daniel E. Soffer, MD, FNLA

Program Planner
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA



FACULTY

Zahid Ahmad, MD

Associate Professor of Internal Medicine
Co-Director, Familial Hypercholesterolemia Clinic
UT Southwestern Medical Center
Dallas, TX

Christie M. Ballantyne, MD, FNLA

Committee Co-Chair
Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Houston, TX

Michael J. Blaha, MD, MPH

Director of Clinical Research
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Baltimore, MD

Eliot A. Brinton, MD, FNLA

President
Utah Lipid Center
Salt Lake City, UT

Emily E. Brown, MGC, CGC

Certified Genetic Counselor
Center for Inherited Heart Disease
Johns Hopkins University
Baltimore, MD

 

 

 

Matthew J. Budoff, MD

Professor of Medicine
UCLA School of Medicine
Program Director, Cardiology
Lundquist Institute
Torrance, CA

Alberico L. Catapano, PhD

Professor of Pharmacology
Director
Center of Epidemiology and Preventive Pharmacology
Director
Laboratory of Lipoproteins, Immunity and Atherosclerosis
Department of Pharmacological and Biomolecular Sciences Director
Center for the Study of Atherosclerosis
Bassini Hospital
University of Milan                           
Milan, Italy

 

Nihar R. Desai, MD, MPH

Associate Professor of Medicine
Yale School of Medicine
Associate Chief
Section of Cardiovascular Medicine
Yale New Haven Health System
New Haven, CT

G. Kevin Donovan, MD, MA

Director
Pellegrino Center for Clinical Bioethics
Professor of Pediatrics
Georgetown University Medical Center
Washington, DC

Eugenia Gianos, MD, FNLA

System Director
Cardiovascular Prevention
Northwell Health
Director
Women's Cardiovascular Program
Lenox Hill Hospital
Associate Professor of Cardiology
Hofstra School of Medicine
New York, NY

John R. Guyton, MD, FNLA

Professor of Medicine
Assistant Professor of Pathology
Department of Medicine
Duke University School of Medicine
Durham, NC

Alizah Hussain, MD

PGY4, Lipid and Atherosclerosis Fellow
Baylor College of Medicine
Houston, TX

Peter H. Jones, MD, FNLA

Program Planner
Associate Professor
Baylor College of Medicine
Houston, TX

Dinesh Kalra, MD

Director
Lipid Clinic and Advanced Cardiac Imaging
Division of Cardiology
Rush University Medical Center
Chicago, IL

Wahida Karmally, PhD, DrPH, RDN, CDE, CLS, FNLA

Columbia University
New York, NY

Joshua W. Knowles, MD

Assistant Professor
Cardiovascular Medicine and Cardiovascular Institute
Stanford University
Chief Research Advisor
The FH Foundation
Stanford, CA

Ann M. Liebeskind, MD, FNLA

President, Midwest Chapter Lipid Association
Founder
Mobile Health Team Lipids Clinic
Neenah, WI
Clinical Adjunct Assistant Professor
University of Wisconsin
School of Medicine and Public Health
Madison, WI

Pamela B. Morris, MD, FNLA

Program Planner
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Mt. Pleasant, SC

Carl E. Orringer, MD, FNLA

Associate Professor of Clinical Medicine
Director
Preventive Cardiovascular Medicine
University of Miami Miller School of Medicine
Miami, FL

Maamoun Salam, MD

Assistant Professor of Medicine
Division of Endocrinology, Metabolism and Lipid  Research
Washington University
St. Louis, MO

James H. Stein, MD, FNLA

Robert Turell Professor in Cardiovascular Research
Director
Atherosclerosis Imaging Research Program
University of Wisconsin
School of Medicine and Public Health
Director
Preventive Cardiology
UW Health
Madison, WI

Nathan O. Stitziel, MD, PhD

Associate Professor of Medicine and Genetics
Director
Center for Cardiovascular Genetics
Washington University School of Medicine
St. Louis, MO

Pam R. Taub, MD

Director
Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Associate Professor of Medicine
Department of Cardiovascular Medicine
University of California, San Diego
La Jolla, CA

Jennifer L. Thompson, MD

Assistant Professor Obstetrics and Gynecology
Fellowship Program Director
Maternal Fetal Medicine
Vanderbilt University Medical Center
Nashville, TN

Lale Tokgözoğlu, MD

President, European Atherosclerosis Society
Professor of Cardiology
Hacettepe University
Ankara, Turkey

James A. Trippi, MD, FNLA

Director
Complex Cholesterol Center
Cardiometabolic Center
Ascension- St. Vincent Health
Indianapolis, IN

Elaine M. Urbina, MD, MS

Director
Preventive Cardiology
Cincinnati Children's Hospital Medical Center
Cincinnati, OH

John M. Vierling, MD

Professor of Medicine and Surgery
Chief of Hepatology
Director of Advanced Liver Therapies
Baylor College of Medicine
Houston, TX

Krishnaswami Vijayaraghavan, MD, MS, FNLA

Executive Council Chair, National Lipid Association
Medical Director
CHF, Abrazo Health Network
Clinical Professor of Medicine
University of Arizona
Phoenix, AZ

Michael Wilkinson, MD

Assistant Professor of Medicine
Division of Cardiovascular Medicine
University of California, San Diego
La Jolla, CA

Don P. Wilson, MD, FNLA

Director
Pediatric CV Health and Risk Reduction
Cook Children’s Medical Center’
Fort Worth, TX



Register for 2020 Scientific Sessions

Registration Options






NLA Member Pricing
*Must be logged in


Main Session

December 10-12, 2020


Masters in Lipidology

December 3-4, 2020


Foundations of Lipidology

November 19-20, 2020


Non-Member Pricing


Main Session

December 10-12, 2020

OR

Join the NLA and save on registration

$195.00 NLA Member Applicaton + $299.00 Main Session Registration - $50.00 New Member Discount

Masters in Lipidology

December 3-4, 2020


Foundations of Lipidology

November 19-20, 2020


Trainee Pricing
*Must be logged in


Main Session

December 10-12, 2020


Masters in Lipidology

December 3-4, 2020


Foundations of Lipidology

November 19-20, 2020


Interested in the Trainee Rate?


Enrolled in a graduate or postgraduate training program and want to attend at the Trainee Member rate?

Apply now for free





Disclaimer


Lipid Bucks: Lipid Bucks can be applied on the checkout page.

Registration: Online registration and payment must be received no later than December 9, 2020. By registering for this meeting, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By visiting the virtual exhibit hall, attendee understands, agrees and consents to the sharing of attendee’s contact information with the participating companies.

Photography: Photographs and/or video may be taken as part of the registered event. By registering for this event, you grant the National Lipid Association full rights to use the images resulting from the photography/video filming and any reproductions or adaptations of the images for promotional purposes. This may include (but is not limited to), the right to use them in print and online platforms, social media, press releases and other outlets.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than November 10, 2020. There will be a $50 fee for all cancellations. There will be no refunds if cancelling within 30 days of the start of the meeting date.

Attendees who need special reasonable accommodations or who have special needs should contact the meeting organizers at 904-998-0854.